Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML). Ivosidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute liver injury.
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.
Ivosidenib is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide, and a secondary carboxamide.
Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.[rx] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to the differentiation of malignant cells.[rx]
Ivosidenib was approved for medical use in the United States in July 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[rx]
Mechanism of Action
Ivosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild-type enzyme. It is considered to be a slow-binder of the wild-type enzyme and binds to mutant enzymes at lower concentrations, both of which may contribute to its selectivity. Ivosidenib has not been observed to inhibit any form of IDH2 at micromolar concentrations.
Many cancers undergo missense mutations of their IDH1 gene leading to the substitution of arginine 132 residues of the IDH1 enzyme [A35629. This substitution leads to reduced production of the normal carboxylic acid cycle metabolite α-ketoglutarate (α-KG) in favor of a new metabolite, D-2-hydroxyglutarate (D-2HG) which reaches levels of 50-100 fold that of wild type cells. D-2HG is a weak competitor to α-KG, inhibiting aKG-dependent dioxygenases, and is present. These dioxygenases include several histone demethylases. This leads to hypermethylation of histones, a dominant feature of AML, which is associated with less expression of cell-differentiation genes. Furthermore, methylation-sensitive insulators can no longer regulate the activation of oncogenes when histones are hypermethylated. In AML this hypermethylation is known to disrupt hematopoietic differentiation. Ivosidenib reduces the production of D-2HG, relieving the inhibition of histone demethylases and restoring normal methylation conditions. This restores cell differentiation and oncogene regulation leading to the regression of cancer.
Indications
- Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML).
- Ivosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test.
- Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumors, hematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of the central nervous system
- Treatment of acute myeloid leukemia. Locally Advanced or Metastatic Cholangiocarcinoma in adults who have been previously treated.
- Ivosidenib is indicated for people with acute myeloid leukemia and locally advanced or metastatic cholangiocarcinoma.
- Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) in combination azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.[rx] Relapsed or refractory AML in adults.[rx]
- Acute Myeloid Leukemia
- Locally Advanced Cholangiocarcinoma
- Metastatic Cholangiocarcinoma
- Refractory Acute Myeloid Leukemia (AML)
- Relapsed Acute Myelogenous Leukemia (AML)
Use in Cancer
Ivosidenib is approved to treat adults whose cancer has a certain mutation in the IDH1 gene, including:
- Acute myeloid leukemia (AML). It is used:
- Alone or with azacitidine in patients with newly-diagnosed cancer who are aged 75 years and older or who, due to health problems, cannot receive intensive induction chemotherapy.
- When cancer has come back or has not gotten better after previous treatment.
- Cholangiocarcinoma (bile duct cancer) has spread. It is used in adults whose cancer has been treated.
Ivosidenib is also being studied in the treatment of other types of cancer.
Contraindications
- low amount of magnesium in the blood
- low amount of calcium in the blood
- low amount of potassium in the blood
- Guillain-Barre syndrome
- torsades de pointes, a type of abnormal heart rhythm
- prolonged QT interval on EKG
- chronic heart failure
- abnormal EKG with QT changes from birth
- pregnancy
- a patient who is producing milk and breastfeeding
Dosage
Strengths: 250 mg
Acute Myeloid Leukemia
- 500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response. Select patients for the treatment of AML based on the presence of IDH1 mutations in the blood or bone marrow. Patients without IDH1 mutations at diagnosis should be retested at relapse because a mutation in IDH1 may emerge during therapy and at relapse.
- For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Acute Myeloid Leukemia
75 years or older:
- 500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
- For the treatment of adult patients with newly-diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are 75 years older or who have comorbidities that preclude the use of intensive induction chemotherapy.
Renal Dose Adjustments
- Mild (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min): No adjustment is recommended.
- Severe renal impairment (CrCl less than 30 mL/min): Data not available
Liver Dose Adjustments
- Mild hepatic impairment (total bilirubin less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase [AST] greater than ULN or total bilirubin 1 to 1.5 x ULN and any AST): No adjustment recommended.
- Moderate hepatic impairment (total bilirubin 1.5 to 3.0 x ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3 x ULN and any value for AST): Data not available
Dose Adjustments
DIFFERENTIATION SYNDROME:
- If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days.
- Interrupt therapy if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids. Resume therapy when signs and symptoms improve to Grade 2 or less.
NONINFECTIOUS LEUKOCYTOSIS (white blood cell [WBC] count greater than 25 x 10(9)/L or an absolute increase in total WBC of greater than 15 x 10(9)/L from baseline):
- Initiate treatment with hydroxyurea, as per standard institutional practices, and leukapheresis if clinically indicated.
- Taper hydroxyurea only after leukocytosis improves or resolves.
- Interrupt therapy if leukocytosis is not improved with hydroxyurea, and then resume therapy at 500 mg daily when leukocytosis has resolved.
QTC INTERVAL GREATER THAN 480 MSEC TO 500 MSEC:
- Monitor and supplement electrolyte levels as clinically indicated.
- Review and adjust concomitant medications with known QTc interval-prolonging effects.
- Interrupt therapy.
- Restart therapy at 500 mg once daily after the QTc interval returns to less or equal to 480 msec.
- Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.
QTC INTERVAL GREATER THAN 500 MSEC:
- Monitor and supplement electrolyte levels as clinically indicated.
- Review and adjust concomitant medications with known QTc interval-prolonging effects.
- Interrupt therapy.
- Resume therapy at a reduced dose of 250 mg once daily when the QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.
- Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.
- Consider re-escalating the dose to 500 mg daily if an alternative etiology for QTc prolongation can be identified.
QTC INTERVAL PROLONGATION WITH SIGNS/SYMPTOMS OF LIFE-THREATENING ARRHYTHMIA:
- Discontinue therapy permanently.
GUILLAIN-BARRE SYNDROME:
- Discontinue therapy permanently.
OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED TO BE RELATED TO TREATMENT:
- Interrupt therapy until toxicity resolves to Grade 2 or lower.
- Resume therapy at 250 mg once daily; may increase to 500 mg once daily if toxicities resolve to Grade 1 or lower.
- If Grade 3 or higher toxicity recurs, discontinue therapy.
DOSE MODIFICATION FOR USE WITH STRONG CYP450 3A4 INHIBITORS
- If a strong CYP450 3A4 inhibitor must be coadministered, reduce the dose of this drug to 250 mg once daily.
- If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug (after at least 5 half-lives of the strong CYP450 3A4 inhibitor) to the recommended dose of 500 mg once daily.
Administration advice:
- This drug may be taken with or without food; however, it should not be administered with a high-fat meal because of an increase in drug concentration.
- Do not split or crush tablets.
- Administer this drug at about the same time each day.
- If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due.
- If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.
- Assess blood counts and blood chemistries prior to the initiation of therapy, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy.
- Monitor blood creatine phosphokinase weekly for the first month of therapy.
- Monitor electrocardiograms (ECGs) at least once weekly for the first 3 weeks of therapy and then at least once monthly for the duration of therapy. Manage any abnormalities promptly.
Side Effects
The Most Common
- headache
- fatigue
- joint or muscle pain
- diarrhea
- constipation
- vomiting
- nausea
- decreased appetite
- mouth pain and ulcers
- stomach pain
- difficulty falling asleep or staying asleep
- dizziness, lightheadedness, or fainting
- weakness or tingling sensation in legs, arms, or upper body; numbness and pain on one side or both sides of the body; changes in your ability to see, touch, hear, or taste; burning or prickling sensation; or difficulty breathing
- chest pain
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- blurred vision
- burning, tingling, numbness or pain in the hands, arms, feet, or legs
- chest pain or tightness
- chills
- confusion
- cough
- decreased urination
- difficult or labored breathing
- difficulty in moving
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- eye pain
- fainting
- fever
- general feeling of illness
- headache
- irregular heartbeat, recurrent
- joint pain, stiffness, or swelling
- lower back, side, or stomach pain
- muscle ache, cramps, pain, or stiffness
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- rapid weight gain
- rash
- the sensation of pins and needles
- sore throat
- sores, ulcers, or white spots on the lips, tongue, or inside the mouth
- stabbing pain
- swelling of your arms, feet, or lower legs
- unusual bleeding or bruising
- unusual tiredness or weakness
Rare
- Inability to move the arms and legs
- sudden numbness and weakness in the arms and legs
- Cracked lips
- decreased appetite
- diarrhea
- difficulty in swallowing
- nausea
- vomiting
- decreased urination;
- rapid weight gain; or
- swelling in your arms or legs.
- fast or pounding heartbeats, fluttering in your chest, shortness of breath, sudden dizziness (like you might pass out);
- jaundice (yellowing of the skin or eyes);
- fluid build-up around the stomach–rapid weight gain, stomach pain and bloating, trouble breathing while lying down;
- low red blood cells (anemia)–pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet;
- high white blood cell counts–fever, weakness, not feeling well, bleeding or bruising, nausea, loss of appetite, weight loss; or
- nervous system problems–numbness, pain, tingling, weakness, burning or prickly feeling, vision or hearing problems, trouble breathing.
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| 1,2-Benzodiazepine | The metabolism of 1,2-Benzodiazepine can be increased when combined with Ivosidenib. |
| Abametapir | The serum concentration of Ivosidenib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Ivosidenib can be increased when combined with Abatacept. |
| Abemaciclib | The metabolism of Abemaciclib can be increased when combined with Ivosidenib. |
| Abiraterone | The metabolism of Abiraterone can be increased when combined with Ivosidenib. |
| Abrocitinib | The metabolism of Abrocitinib can be increased when combined with Ivosidenib. |
| Acalabrutinib | The metabolism of Acalabrutinib can be increased when combined with Ivosidenib. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Ivosidenib. |
| Acetaminophen | The metabolism of Acetaminophen can be increased when combined with Ivosidenib. |
| Acetazolamide | The metabolism of Ivosidenib can be decreased when combined with Acetazolamide. |
| Acetohexamide | The metabolism of Acetohexamide can be increased when combined with Ivosidenib. |
| Acetylsalicylic acid | The metabolism of Acetylsalicylic acid can be increased when combined with Ivosidenib. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ivosidenib. |
| Adalimumab | The metabolism of Ivosidenib can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ivosidenib. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ivosidenib. |
| Albendazole | The metabolism of Albendazole can be increased when combined with Ivosidenib. |
| Alclometasone | The metabolism of Alclometasone can be increased when combined with Ivosidenib. |
| Aldesleukin | The metabolism of Ivosidenib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be increased when combined with Ivosidenib. |
| Alfentanil | The metabolism of Alfentanil can be increased when combined with Ivosidenib. |
| Alfuzosin | The metabolism of Alfuzosin can be increased when combined with Ivosidenib. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ivosidenib. |
| Aliskiren | The metabolism of Aliskiren can be increased when combined with Ivosidenib. |
| Almotriptan | The metabolism of Almotriptan can be increased when combined with Ivosidenib. |
| Alogliptin | The metabolism of Alogliptin can be increased when combined with Ivosidenib. |
| Alosetron | The metabolism of Alosetron can be increased when combined with Ivosidenib. |
| Alpelisib | The metabolism of Alpelisib can be increased when combined with Ivosidenib. |
| Alprazolam | The metabolism of Alprazolam can be increased when combined with Ivosidenib. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ivosidenib. |
| Ambrisentan | The metabolism of Ambrisentan can be increased when combined with Ivosidenib. |
| Ambroxol | The metabolism of Ambroxol can be increased when combined with Ivosidenib. |
| Amcinonide | The metabolism of Amcinonide can be increased when combined with Ivosidenib. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Ivosidenib. |
| Aminoglutethimide | The metabolism of Ivosidenib can be increased when combined with Aminoglutethimide. |
| Aminophenazone | The metabolism of Aminophenazone can be increased when combined with Ivosidenib. |
| Aminophylline | The metabolism of Aminophylline can be increased when combined with Ivosidenib. |
| Amiodarone | The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Ivosidenib. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Amisulpride. |
| Amitriptyline | The metabolism of Amitriptyline can be increased when combined with Ivosidenib. |
| Amlodipine | The metabolism of Amlodipine can be increased when combined with Ivosidenib. |
| Amobarbital | The metabolism of Ivosidenib can be increased when combined with Amobarbital. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ivosidenib. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ivosidenib. |
| Amprenavir | The metabolism of Ivosidenib can be decreased when combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Ivosidenib. |
| Anakinra | The metabolism of Ivosidenib can be increased when combined with Anakinra. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Ivosidenib. |
| Antipyrine | The metabolism of Antipyrine can be increased when combined with Ivosidenib. |
| Apalutamide | The metabolism of Ivosidenib can be increased when combined with Apalutamide. |
| Apixaban | The metabolism of Apixaban can be increased when combined with Ivosidenib. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ivosidenib. |
| Apremilast | The metabolism of Apremilast can be increased when combined with Ivosidenib. |
| Aprepitant | The metabolism of Ivosidenib can be decreased when combined with Aprepitant. |
| Arformoterol | The metabolism of Arformoterol can be increased when combined with Ivosidenib. |
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Ivosidenib. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be increased when combined with Ivosidenib. |
| Armodafinil | The metabolism of Ivosidenib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ivosidenib. |
| Artemether | The risk or severity of QTc prolongation can be increased when Artemether is combined with Ivosidenib. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Articaine. |
| Asciminib | The serum concentration of Ivosidenib can be increased when it is combined with Asciminib. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Asenapine is combined with Ivosidenib. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Astemizole is combined with Ivosidenib. |
| Asunaprevir | The metabolism of Asunaprevir can be increased when combined with Ivosidenib. |
| Atazanavir | The metabolism of Ivosidenib can be decreased when combined with Atazanavir. |
| Atogepant | The metabolism of Atogepant can be increased when combined with Ivosidenib. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ivosidenib. |
| Atorvastatin | The metabolism of Atorvastatin can be increased when combined with Ivosidenib. |
| Atovaquone | The metabolism of Atovaquone can be increased when combined with Ivosidenib. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Ivosidenib. |
| Avacopan | The metabolism of Avacopan can be increased when combined with Ivosidenib. |
| Avanafil | The metabolism of Avanafil can be increased when combined with Ivosidenib. |
| Avapritinib | The metabolism of Avapritinib can be increased when combined with Ivosidenib. |
| Axitinib | The metabolism of Axitinib can be increased when combined with Ivosidenib. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ivosidenib. |
| Azelastine | The metabolism of Azelastine can be increased when combined with Ivosidenib. |
| Azithromycin | The metabolism of Azithromycin can be increased when combined with Ivosidenib. |
| Baricitinib | The metabolism of Baricitinib can be increased when combined with Ivosidenib. |
| Beclomethasone | The metabolism of Beclomethasone dipropionate can be increased when combined with Ivosidenib. |
| Bedaquiline | The metabolism of Bedaquiline can be increased when combined with Ivosidenib. |
| Belumosudil | The metabolism of Belumosudil can be increased when combined with Ivosidenib. |
| Belzutifan | The serum concentration of Ivosidenib can be decreased when it is combined with Belzutifan. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ivosidenib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Benzocaine. |
| Benzphetamine | The metabolism of Benzphetamine can be increased when combined with Ivosidenib. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Benzyl alcohol. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Bepridil is combined with Ivosidenib. |
| Berotralstat | The serum concentration of Ivosidenib can be increased when it is combined with Berotralstat. |
| Betamethasone | The metabolism of Betamethasone can be increased when combined with Ivosidenib. |
| Betamethasone | The metabolism of Betamethasone phosphate can be increased when combined with Ivosidenib. |
| Bexarotene | The metabolism of Bexarotene can be increased when combined with Ivosidenib. |
| Bezafibrate | The metabolism of Bezafibrate can be increased when combined with Ivosidenib. |
| Bicalutamide | The metabolism of Bicalutamide can be increased when combined with Ivosidenib. |
| Bictegravir | The metabolism of Bictegravir can be increased when combined with Ivosidenib. |
| Bifonazole | The metabolism of Ivosidenib can be decreased when combined with Bifonazole. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Ivosidenib. |
| Bimekizumab | The metabolism of Ivosidenib can be increased when combined with Bimekizumab. |
| Bioallethrin | The metabolism of Bioallethrin can be increased when combined with Ivosidenib. |
| Bisoprolol | The metabolism of Bisoprolol can be increased when combined with Ivosidenib. |
| Boceprevir | The metabolism of Ivosidenib can be decreased when combined with Boceprevir. |
| Bortezomib | The metabolism of Bortezomib can be increased when combined with Ivosidenib. |
| Bosentan | The metabolism of Bosentan can be increased when combined with Ivosidenib. |
| Bosutinib | The metabolism of Bosutinib can be increased when combined with Ivosidenib. |
| Brentuximab | The metabolism of Brentuximab vedotin can be increased when combined with Ivosidenib. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Ivosidenib. |
| Brexpiprazole | The metabolism of Brexpiprazole can be increased when combined with Ivosidenib. |
| Brigatinib | The metabolism of Brigatinib can be increased when combined with Ivosidenib. |
| Brinzolamide | The metabolism of Brinzolamide can be increased when combined with Ivosidenib. |
| Brivaracetam | The metabolism of Brivaracetam can be increased when combined with Ivosidenib. |
| Bromocriptine | The metabolism of Bromocriptine can be increased when combined with Ivosidenib. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Ivosidenib. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ivosidenib. |
| Budesonide | The metabolism of Budesonide can be increased when combined with Ivosidenib. |
| Bupivacaine | The metabolism of Bupivacaine can be increased when combined with Ivosidenib. |
| Buprenorphine | The metabolism of Buprenorphine can be increased when combined with Ivosidenib. |
| Bupropion | The metabolism of Bupropion can be increased when combined with Ivosidenib. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ivosidenib. |
| Buspirone | The metabolism of Buspirone can be increased when combined with Ivosidenib. |
| Busulfan | The metabolism of Busulfan can be increased when combined with Ivosidenib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Butacaine. |
| Butalbital | The metabolism of Ivosidenib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Ivosidenib. |
| Cabazitaxel | The metabolism of Cabazitaxel can be increased when combined with Ivosidenib. |
| Cabergoline | The metabolism of Cabergoline can be increased when combined with Ivosidenib. |
| Cabozantinib | The metabolism of Cabozantinib can be increased when combined with Ivosidenib. |
| Calcitriol | The metabolism of Calcitriol can be increased when combined with Ivosidenib. |
| Canagliflozin | The metabolism of Canagliflozin can be increased when combined with Ivosidenib. |
| Canakinumab | The metabolism of Ivosidenib can be increased when combined with Canakinumab. |
| Candesartan cilexetil | The metabolism of Candesartan cilexetil can be increased when combined with Ivosidenib. |
| Candicidin | The metabolism of Ivosidenib can be decreased when combined with Candicidin. |
| Cannabidiol | The metabolism of Cannabidiol can be increased when combined with Ivosidenib. |
| Capecitabine | The metabolism of Capecitabine can be increased when combined with Ivosidenib. |
| Capmatinib | The serum concentration of Capmatinib can be decreased when it is combined with Ivosidenib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Ivosidenib can be increased when combined with Carbamazepine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Ivosidenib. |
| Cariprazine | The metabolism of Cariprazine can be increased when combined with Ivosidenib. |
| Carvedilol | The metabolism of Carvedilol can be increased when combined with Ivosidenib. |
| Cefradine | The metabolism of Ivosidenib can be increased when combined with Cefradine. |
| Celecoxib | The metabolism of Celecoxib can be increased when combined with Ivosidenib. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Ivosidenib. |
| Cenobamate | The serum concentration of Ivosidenib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Cephalexin can be increased when combined with Ivosidenib. |
| Ceritinib | The metabolism of Ceritinib can be increased when combined with Ivosidenib. |
| Cerivastatin | The metabolism of Cerivastatin can be increased when combined with Ivosidenib. |
| Certolizumab pegol | The metabolism of Ivosidenib can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ivosidenib. |
| Cevimeline | The metabolism of Cevimeline can be increased when combined with Ivosidenib. |
| Chenodeoxycholic | The metabolism of Chenodeoxycholic acid can be increased when combined with Ivosidenib. |
| Chloramphenicol | The metabolism of Ivosidenib can be decreased when combined with Chloramphenicol. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ivosidenib. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Chloroprocaine. |
| Chloroquine | The metabolism of Chloroquine can be increased when combined with Ivosidenib. |
| Chlorpheniramine | The metabolism of Chlorpheniramine can be increased when combined with Ivosidenib. |
| Chlorpromazine | The metabolism of Chlorpromazine can be increased when combined with Ivosidenib. |
| Chlorpropamide | The metabolism of Chlorpropamide can be increased when combined with Ivosidenib. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ivosidenib. |
| Chlorzoxazone | The metabolism of Chlorzoxazone can be increased when combined with Ivosidenib. |
| Cholecalciferol | The metabolism of Cholecalciferol can be increased when combined with Ivosidenib. |
| Ciclesonide | The metabolism of Ciclesonide can be increased when combined with Ivosidenib. |
| Cilostazol | The metabolism of Cilostazol can be increased when combined with Ivosidenib. |
| Cimetidine | The metabolism of Ivosidenib can be decreased when combined with Cimetidine. |
| Cinacalcet | The metabolism of Cinacalcet can be increased when combined with Ivosidenib. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Cinchocaine. |
| Cinnarizine | The metabolism of Cinnarizine can be increased when combined with Ivosidenib. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Ivosidenib. |
| Ciprofloxacin | The metabolism of Ivosidenib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Cisapride is combined with Ivosidenib. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ivosidenib. |
| Clarithromycin | The metabolism of Ivosidenib can be decreased when combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Clemastine is combined with Ivosidenib. |
| Clevidipine | The metabolism of Clevidipine can be increased when combined with Ivosidenib. |
| Clindamycin | The metabolism of Clindamycin can be increased when combined with Ivosidenib. |
| Clobazam | The metabolism of Clobazam can be increased when combined with Ivosidenib. |
| Clobetasol | The metabolism of Clobetasol can be increased when combined with Ivosidenib. |
| Clobetasol pro | The metabolism of Clobetasol propionate can be increased when combined with Ivosidenib. |
| Clobetasone | The metabolism of Clobetasone can be increased when combined with Ivosidenib. |
| Clofazimine | The metabolism of Ivosidenib can be decreased when combined with Clofazimine. |
| Clofibrate | The metabolism of Clofibrate can be increased when combined with Ivosidenib. |
| Clomipramine | The metabolism of Clomipramine can be increased when combined with Ivosidenib. |
| Clonazepam | The metabolism of Clonazepam can be increased when combined with Ivosidenib. |
| Clonidine | The metabolism of Clonidine can be increased when combined with Ivosidenib. |
| Clopidogrel | The metabolism of Clopidogrel can be increased when combined with Ivosidenib. |
| Clorazepic acid | The metabolism of Clorazepic acid can be increased when combined with Ivosidenib. |
| Clotiazepam | The metabolism of Clotiazepam can be increased when combined with Ivosidenib. |
| Clozapine | The metabolism of Ivosidenib can be decreased when combined with Clozapine. |
| Cobicistat | The metabolism of Ivosidenib can be decreased when combined with Cobicistat. |
| Cobimetinib | The metabolism of Cobimetinib can be increased when combined with Ivosidenib. |
| Cocaine | The risk or severity of QTc prolongation can be increased when Cocaine is combined with Ivosidenib. |
| Codeine | The metabolism of Codeine can be increased when combined with Ivosidenib. |
| Colchicine | The metabolism of Colchicine can be increased when combined with Ivosidenib. |
| Conivaptan | The metabolism of Ivosidenib can be decreased when combined with Conivaptan. |
| Conjugated es | The metabolism of Conjugated estrogens can be increased when combined with Ivosidenib. |
| Copanlisib | The metabolism of Copanlisib can be increased when combined with Ivosidenib. |
| Corticotropin | The metabolism of Corticotropin can be increased when combined with Ivosidenib. |
| Cortisone acetate | The metabolism of Cortisone acetate can be increased when combined with Ivosidenib. |
| Crizotinib | The metabolism of Ivosidenib can be decreased when combined with Crizotinib. |
| Curcumin | The metabolism of Ivosidenib can be decreased when combined with Curcumin. |
| Cyclandelate | The metabolism of Cyclandelate can be increased when combined with Ivosidenib. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ivosidenib. |
| Cyclobenzaprine | The metabolism of Cyclobenzaprine can be increased when combined with Ivosidenib. |
| Cyclophosphamide | The metabolism of Cyclophosphamide can be increased when combined with Ivosidenib. |
| Cyclosporine | The metabolism of Ivosidenib can be decreased when combined with Cyclosporine. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ivosidenib. |
| Cyproterone ac | The metabolism of Cyproterone acetate can be increased when combined with Ivosidenib. |
| Dabrafenib | The metabolism of Dabrafenib can be increased when combined with Ivosidenib. |
| Daclatasvir | The metabolism of Daclatasvir can be increased when combined with Ivosidenib. |
| Dacomitinib | The metabolism of Dacomitinib can be increased when combined with Ivosidenib. |
| Dalfopristin | The metabolism of Ivosidenib can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Ivosidenib can be decreased when combined with Danazol. |
| Dapagliflozin | The metabolism of Dapagliflozin can be increased when combined with Ivosidenib. |
| Dapsone | The metabolism of Dapsone can be increased when combined with Ivosidenib. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ivosidenib. |
| Daridorexant | The metabolism of Daridorexant can be increased when combined with Ivosidenib. |
| Darifenacin | The metabolism of Darifenacin can be increased when combined with Ivosidenib. |
| Darolutamide | The metabolism of Darolutamide can be increased when combined with Ivosidenib. |
| Darunavir | The serum concentration of Ivosidenib can be increased when it is combined with Darunavir. |
| Dasabuvir | The metabolism of Dasabuvir can be increased when combined with Ivosidenib. |
| Dasatinib | The metabolism of Dasatinib can be increased when combined with Ivosidenib. |
| Daunorubicin | The metabolism of Ivosidenib can be decreased when combined with Daunorubicin. |
| Deferasirox | The metabolism of Ivosidenib can be increased when combined with Deferasirox. |
| Deflazacort | The metabolism of Deflazacort can be increased when combined with Ivosidenib. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ivosidenib. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ivosidenib. |
| Delamanid | The metabolism of Delamanid can be increased when combined with Ivosidenib. |
| Delavirdine | The metabolism of Ivosidenib can be decreased when combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ivosidenib. |
| Desipramine | The metabolism of Ivosidenib can be decreased when combined with Desipramine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Ivosidenib. |
| Desogestrel | The metabolism of Desogestrel can be increased when combined with Ivosidenib. |
| Desonide | The metabolism of Desonide can be increased when combined with Ivosidenib. |
| Desoxycorticost | The metabolism of Desoxycorticosterone acetate can be increased when combined with Ivosidenib. |
| Desvenlafaxine | The metabolism of Ivosidenib can be decreased when combined with Desvenlafaxine. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Ivosidenib. |
| Dexamethasone | The metabolism of Ivosidenib can be increased when combined with Dexamethasone. |
| Dexamethasone ac | The metabolism of Dexamethasone acetate can be increased when combined with Ivosidenib. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ivosidenib. |
| Dexchlorpheniramine | The metabolism of Dexchlorpheniramine maleate can be increased when combined with Ivosidenib. |
| Dexibuprofen | The metabolism of Dexibuprofen can be increased when combined with Ivosidenib. |
| Dexlansoprazole | The metabolism of Dexlansoprazole can be increased when combined with Ivosidenib. |
| Dextromethorphan | The metabolism of Dextromethorphan can be increased when combined with Ivosidenib. |
| Dextropropoxyphene | The metabolism of Dextropropoxyphene can be increased when combined with Ivosidenib. |
| Diazepam | The metabolism of Diazepam can be increased when combined with Ivosidenib. |
| Diclofenac | The metabolism of Diclofenac can be increased when combined with Ivosidenib. |
| Dicloxacillin | The metabolism of Ivosidenib can be increased when combined with Dicloxacillin. |
| Dicoumarol | The metabolism of Dicoumarol can be increased when combined with Ivosidenib. |
| Dienogest | The metabolism of Dienogest can be increased when combined with Ivosidenib. |
| Diethylstilbestrol | The metabolism of Diethylstilbestrol can be increased when combined with Ivosidenib. |
| Difluocortolone | The metabolism of Difluocortolone can be increased when combined with Ivosidenib. |
| Difluprednate | The metabolism of Difluprednate can be increased when combined with Ivosidenib. |
| Digitoxin | The metabolism of Digitoxin can be increased when combined with Ivosidenib. |
| Digoxin | The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ivosidenib. |
| Dihydro-alpha-e | The metabolism of Dihydro-alpha-ergocryptine can be increased when combined with Ivosidenib. |
| Dihydrocodeine | The metabolism of Dihydrocodeine can be increased when combined with Ivosidenib. |
| Dihydroergocornine | The metabolism of Dihydroergocornine can be increased when combined with Ivosidenib. |
| Dihydroergocristine | The metabolism of Dihydroergocristine can be increased when combined with Ivosidenib. |
| Dihydroergotamine | The metabolism of Dihydroergotamine can be increased when combined with Ivosidenib. |
| Diltiazem | The metabolism of Ivosidenib can be decreased when combined with Diltiazem. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ivosidenib. |
| Dimethyl sulfoxide | The metabolism of Ivosidenib can be decreased when combined with Dimethyl sulfoxide. |
| Diosmin | The metabolism of Ivosidenib can be decreased when combined with Diosmin. |
| Diphenhydramine | The metabolism of Diphenhydramine can be increased when combined with Ivosidenib. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ivosidenib. |
| Disulfiram | The metabolism of Disulfiram can be increased when combined with Ivosidenib. |
| Docetaxel | The metabolism of Docetaxel can be increased when combined with Ivosidenib. |
| Doconexent | The metabolism of Doconexent can be increased when combined with Ivosidenib. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Ivosidenib. |
| Dolasetron | The metabolism of Dolasetron can be increased when combined with Ivosidenib. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Domperidone is combined with Ivosidenib. |
| Donepezil | The metabolism of Donepezil can be increased when combined with Ivosidenib. |
| Doravirine | The metabolism of Doravirine can be increased when combined with Ivosidenib. |
| Dosulepin | The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ivosidenib. |
| Doxazosin | The metabolism of Doxazosin can be increased when combined with Ivosidenib. |
| Doxepin | The metabolism of Doxepin can be increased when combined with Ivosidenib. |
| Doxorubicin | The metabolism of Doxorubicin can be increased when combined with Ivosidenib. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ivosidenib. |
| Dronabinol | The metabolism of Dronabinol can be increased when combined with Ivosidenib. |
| Dronedarone | The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Ivosidenib. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Ivosidenib. |
| Drospirenone | The metabolism of Drospirenone can be increased when combined with Ivosidenib. |
| Duloxetine | The metabolism of Duloxetine can be increased when combined with Ivosidenib. |
| Duvelisib | The metabolism of Duvelisib can be increased when combined with Ivosidenib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Dyclonine. |
| Dydrogesterone | The metabolism of Dydrogesterone can be increased when combined with Ivosidenib. |
| Ebastine | The metabolism of Ebastine can be increased when combined with Ivosidenib. |
| Echinacea | The metabolism of Ivosidenib can be increased when combined with Echinacea. |
| Econazole | The metabolism of Ivosidenib can be decreased when combined with Econazole. |
| Efavirenz | The metabolism of Ivosidenib can be decreased when combined with Efavirenz. |
| Elbasvir | The metabolism of Elbasvir can be increased when combined with Ivosidenib. |
| Eletriptan | The metabolism of Eletriptan can be increased when combined with Ivosidenib. |
| Elexacaftor | The metabolism of Elexacaftor can be increased when combined with Ivosidenib. |
| Eliglustat | The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Ivosidenib. |
| Elvitegravir | The metabolism of Ivosidenib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Ivosidenib can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Emedastine is combined with Ivosidenib. |
| Enasidenib | The metabolism of Enasidenib can be increased when combined with Ivosidenib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Ivosidenib. |
| Encorafenib | The metabolism of Encorafenib can be increased when combined with Ivosidenib. |
| Enfortumab ve | The metabolism of Enfortumab vedotin can be increased when combined with Ivosidenib. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ivosidenib. |
| Entrectinib | The metabolism of Entrectinib can be increased when combined with Ivosidenib. |
| Enzalutamide | The metabolism of Ivosidenib can be increased when combined with Enzalutamide. |
| Epinastine | The metabolism of Epinastine can be increased when combined with Ivosidenib. |
| Epinephrine | The metabolism of Ivosidenib can be decreased when combined with Epinephrine. |
| Eplerenone | The metabolism of Eplerenone can be increased when combined with Ivosidenib. |
| Eravacycline | The metabolism of Eravacycline can be increased when combined with Ivosidenib. |
| Erdafitinib | The metabolism of Erdafitinib can be increased when combined with Ivosidenib. |
| Ergoloid mesylate | The metabolism of Ergoloid mesylate can be increased when combined with Ivosidenib. |
| Ergometrine | The metabolism of Ergometrine can be increased when combined with Ivosidenib. |
| Ergotamine | The metabolism of Ivosidenib can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ivosidenib. |
| Erlotinib | The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ivosidenib. |
| Erythromycin | The metabolism of Ivosidenib can be decreased when combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ivosidenib. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Ivosidenib. |
| Esketamine | The metabolism of Esketamine can be increased when combined with Ivosidenib. |
| Eslicarbazepine | The metabolism of Ivosidenib can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine | The metabolism of Ivosidenib can be increased when combined with Eslicarbazepine acetate. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ivosidenib. |
| Esomeprazole | The metabolism of Esomeprazole can be increased when combined with Ivosidenib. |
| Estazolam | The metabolism of Estazolam can be increased when combined with Ivosidenib. |
| Esterified estrogen | The metabolism of Esterified estrogens can be increased when combined with Ivosidenib. |
| Estetrol | The metabolism of Estetrol can be increased when combined with Ivosidenib. |
| Estradiol | The metabolism of Estradiol can be increased when combined with Ivosidenib. |
| Estradiol acetate | The metabolism of Estradiol acetate can be increased when combined with Ivosidenib. |
| Estradiol benzoate | The metabolism of Estradiol benzoate can be increased when combined with Ivosidenib. |
| Estradiol cypionate | The metabolism of Estradiol cypionate can be increased when combined with Ivosidenib. |
| Estradiol dienanthate | The metabolism of Estradiol dienanthate can be increased when combined with Ivosidenib. |
| Estradiol valerate | The metabolism of Estradiol valerate can be increased when combined with Ivosidenib. |
| Estramustine | The metabolism of Estramustine can be increased when combined with Ivosidenib. |
| Estrone | The metabolism of Estrone can be increased when combined with Ivosidenib. |
| Estrone sulfate | The metabolism of Estrone sulfate can be increased when combined with Ivosidenib. |
| Eszopiclone | The serum concentration of Eszopiclone can be decreased when it is combined with Ivosidenib. |
| Etanercept | The metabolism of Ivosidenib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Ivosidenib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Ethanol can be increased when combined with Ivosidenib. |
| Ethinylestradiol | The metabolism of Ethinylestradiol can be increased when combined with Ivosidenib. |
| Ethosuximide | The metabolism of Ethosuximide can be increased when combined with Ivosidenib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Ethyl chloride. |
| Ethynodiol diace | The metabolism of Ethynodiol diacetate can be increased when combined with Ivosidenib. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Etidocaine. |
| Etodolac | The metabolism of Etodolac can be increased when combined with Ivosidenib. |
| Etonogestrel | The metabolism of Etonogestrel can be increased when combined with Ivosidenib. |
| Etoposide | The metabolism of Etoposide can be increased when combined with Ivosidenib. |
| Etoricoxib | The metabolism of Etoricoxib can be increased when combined with Ivosidenib. |
| Etravirine | The metabolism of Etravirine can be increased when combined with Ivosidenib. |
| Everolimus | The metabolism of Everolimus can be increased when combined with Ivosidenib. |
| Exemestane | The metabolism of Exemestane can be increased when combined with Ivosidenib. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ivosidenib. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivosidenib. |
| Fedratinib | The metabolism of Fedratinib can be increased when combined with Ivosidenib. |
| Felbamate | The metabolism of Felbamate can be increased when combined with Ivosidenib. |
| Felodipine | The metabolism of Felodipine can be increased when combined with Ivosidenib. |
| Fenofibrate | The metabolism of Fenofibrate can be increased when combined with Ivosidenib. |
| Fentanyl | The metabolism of Fentanyl can be increased when combined with Ivosidenib. |
| Fesoterodine | The metabolism of Fesoterodine can be increased when combined with Ivosidenib. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Ivosidenib is combined with Fexinidazole. |
| Finasteride | The metabolism of Finasteride can be increased when combined with Ivosidenib. |
| Finerenone | The metabolism of Finerenone can be increased when combined with Ivosidenib. |
| Fish oil | The metabolism of Fish oil can be increased when combined with Ivosidenib. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Flecainide is combined with Ivosidenib. |
| Flibanserin | The metabolism of Flibanserin can be increased when combined with Ivosidenib. |
| Flucloxacillin | The metabolism of Ivosidenib can be increased when combined with Flucloxacillin. |
| Fluconazole | The metabolism of Ivosidenib can be decreased when combined with Fluconazole. |
| Fludrocortisone | The metabolism of Fludrocortisone can be increased when combined with Ivosidenib. |
| Fluindione | The metabolism of Fluindione can be increased when combined with Ivosidenib. |
| Flumethasone | The metabolism of Flumethasone can be increased when combined with Ivosidenib. |
| Flunarizine | The metabolism of Flunarizine can be increased when combined with Ivosidenib. |
| Flunisolide | The metabolism of Flunisolide can be increased when combined with Ivosidenib. |
| Flunitrazepam | The metabolism of Flunitrazepam can be increased when combined with Ivosidenib. |
| Fluocinolone | The metabolism of Fluocinolone acetonide can be increased when combined with Ivosidenib. |
| Fluocinonide | The metabolism of Fluocinonide can be increased when combined with Ivosidenib. |
| Fluocortolone | The metabolism of Fluocortolone can be increased when combined with Ivosidenib. |
| Fluorometholone | The metabolism of Fluorometholone can be increased when combined with Ivosidenib. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ivosidenib. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ivosidenib. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Flupentixol. |
| Fluprednisolone | The metabolism of Fluprednisolone can be increased when combined with Ivosidenib. |
| Flurandrenolide | The metabolism of Flurandrenolide can be increased when combined with Ivosidenib. |
| Flurazepam | The metabolism of Flurazepam can be increased when combined with Ivosidenib. |
| Flurbiprofen | The metabolism of Flurbiprofen can be increased when combined with Ivosidenib. |
| Fluspirilene | The metabolism of Fluspirilene can be increased when combined with Ivosidenib. |
| Flutamide | The metabolism of Flutamide can be increased when combined with Ivosidenib. |
| Fluticasone | The metabolism of Fluticasone can be increased when combined with Ivosidenib. |
| Fluticasone furoate | The metabolism of Fluticasone furoate can be increased when combined with Ivosidenib. |
| Fluticasone p | The metabolism of Fluticasone propionate can be increased when combined with Ivosidenib. |
| Fluvastatin | The metabolism of Fluvastatin can be increased when combined with Ivosidenib. |
| Fluvoxamine | The metabolism of Ivosidenib can be decreased when combined with Fluvoxamine. |
| Formestane | The metabolism of Ivosidenib can be increased when combined with Formestane. |
| Formoterol | The metabolism of Formoterol can be increased when combined with Ivosidenib. |
| Fosamprenavir | The metabolism of Fosamprenavir can be increased when combined with Ivosidenib. |
| Fosaprepitant | The metabolism of Fosaprepitant can be increased when combined with Ivosidenib. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ivosidenib. |
| Fosnetupitant | The metabolism of Ivosidenib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Ivosidenib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Fostamatinib can be increased when combined with Ivosidenib. |
| Fostemsavir | The metabolism of Fostemsavir can be increased when combined with Ivosidenib. |
| Fusidic acid | The metabolism of Ivosidenib can be decreased when combined with Fusidic acid. |
| Futibatinib | The metabolism of Futibatinib can be increased when combined with Ivosidenib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Ivosidenib. |
| Galantamine | The metabolism of Galantamine can be increased when combined with Ivosidenib. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ivosidenib. |
| Gefitinib | The metabolism of Gefitinib can be increased when combined with Ivosidenib. |
| Gemfibrozil | The metabolism of Gemfibrozil can be increased when combined with Ivosidenib. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Ivosidenib. |
| Gestrinone | The metabolism of Gestrinone can be increased when combined with Ivosidenib. |
| Gilteritinib | The metabolism of Gilteritinib can be increased when combined with Ivosidenib. |
| Ginkgo biloba | The metabolism of Ivosidenib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ivosidenib. |
| Glecaprevir | The metabolism of Ivosidenib can be decreased when combined with Glecaprevir. |
| Gliclazide | The metabolism of Gliclazide can be increased when combined with Ivosidenib. |
| Glimepiride | The metabolism of Glimepiride can be increased when combined with Ivosidenib. |
| Glipizide | The metabolism of Glipizide can be increased when combined with Ivosidenib. |
| Gliquidone | The metabolism of Gliquidone can be increased when combined with Ivosidenib. |
| Glyburide | The metabolism of Glyburide can be increased when combined with Ivosidenib. |
| Glycerol phen | The metabolism of Ivosidenib can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Ivosidenib can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ivosidenib. |
| Granisetron | The metabolism of Granisetron can be increased when combined with Ivosidenib. |
| Grazoprevir | The metabolism of Grazoprevir can be increased when combined with Ivosidenib. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Ivosidenib. |
| Griseofulvin | The metabolism of Ivosidenib can be increased when combined with Griseofulvin. |
| Guanfacine | The metabolism of Guanfacine can be increased when combined with Ivosidenib. |
| Halcinonide | The metabolism of Halcinonide can be increased when combined with Ivosidenib. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Ivosidenib. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Haloperidol. |
| Halothane | The metabolism of Halothane can be increased when combined with Ivosidenib. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Ivosidenib. |
| Hydralazine | The metabolism of Ivosidenib can be decreased when combined with Hydralazine. |
| Hydrochloroth | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Ivosidenib. |
| Hydrocodone | The metabolism of Hydrocodone can be increased when combined with Ivosidenib. |
| Hydrocortamate | The metabolism of Ivosidenib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Hydrocortisone can be increased when combined with Ivosidenib. |
| Hydrocortisone acet | The metabolism of Hydrocortisone acetate can be increased when combined with Ivosidenib. |
| Hydrocortisone buty | The metabolism of Hydrocortisone butyrate can be increased when combined with Ivosidenib. |
| Hydrocortisone cyp | The metabolism of Hydrocortisone cypionate can be increased when combined with Ivosidenib. |
| Hydrocortisone phosp | The metabolism of Hydrocortisone phosphate can be increased when combined with Ivosidenib. |
| Hydrocortisone pro | The metabolism of Hydrocortisone probutate can be increased when combined with Ivosidenib. |
| Hydrocortisone suc | The metabolism of Hydrocortisone succinate can be increased when combined with Ivosidenib. |
| Hydrocortisone vale | The metabolism of Hydrocortisone valerate can be increased when combined with Ivosidenib. |
| Hydromorphone | The metabolism of Hydromorphone can be increased when combined with Ivosidenib. |
| Hydroxychloroquine | The metabolism of Hydroxychloroquine can be increased when combined with Ivosidenib. |
| Hydroxyprogesterone | The metabolism of Hydroxyprogesterone caproate can be increased when combined with Ivosidenib. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ivosidenib. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivosidenib. |
| Ibrexafungerp | The metabolism of Ibrexafungerp can be increased when combined with Ivosidenib. |
| Ibrutinib | The metabolism of Ibrutinib can be increased when combined with Ivosidenib. |
| Ibuprofen | The metabolism of Ibuprofen can be increased when combined with Ivosidenib. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Ivosidenib. |
| Idarubicin | The metabolism of Idarubicin can be increased when combined with Ivosidenib. |
| Idelalisib | The metabolism of Idelalisib can be increased when combined with Ivosidenib. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Ivosidenib. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Ivosidenib. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Imatinib is combined with Ivosidenib. |
| Imipramine | The metabolism of Imipramine can be increased when combined with Ivosidenib. |
| Imiquimod | The metabolism of Imiquimod can be increased when combined with Ivosidenib. |
| Indacaterol | The metabolism of Indacaterol can be increased when combined with Ivosidenib. |
| Indapamide | The metabolism of Indapamide can be increased when combined with Ivosidenib. |
| Indinavir | The metabolism of Ivosidenib can be decreased when combined with Indinavir. |
| Indomethacin | The metabolism of Indomethacin can be increased when combined with Ivosidenib. |
| Infigratinib | The metabolism of Infigratinib can be increased when combined with Ivosidenib. |
| Infliximab | The metabolism of Ivosidenib can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Ivosidenib. |
| Ipecac | The metabolism of Ipecac can be increased when combined with Ivosidenib. |
| Irbesartan | The metabolism of Irbesartan can be increased when combined with Ivosidenib. |
| Irinotecan | The metabolism of Irinotecan can be increased when combined with Ivosidenib. |
| Isavuconazole | The metabolism of Ivosidenib can be decreased when combined with Isavuconazole. |
| Isavuconazonium | The metabolism of Ivosidenib can be decreased when combined with Isavuconazonium. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ivosidenib. |
| Isoniazid | The metabolism of Ivosidenib can be decreased when combined with Isoniazid. |
| Isotretinoin | The metabolism of Isotretinoin can be increased when combined with Ivosidenib. |
| Isradipine | The metabolism of Ivosidenib can be decreased when combined with Isradipine. |
| Istradefylline | The metabolism of Istradefylline can be increased when combined with Ivosidenib. |
| Itraconazole | The metabolism of Ivosidenib can be decreased when combined with Itraconazole. |
| Ivabradine | The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Ivosidenib. |
| Ivacaftor | The metabolism of Ivacaftor can be increased when combined with Ivosidenib. |
| Ivermectin | The metabolism of Ivermectin can be increased when combined with Ivosidenib. |
| Ixabepilone | The metabolism of Ixabepilone can be increased when combined with Ivosidenib. |
| Ixazomib | The metabolism of Ixazomib can be increased when combined with Ivosidenib. |
| Ketamine | The metabolism of Ketamine can be increased when combined with Ivosidenib. |
| Ketazolam | The metabolism of Ketazolam can be increased when combined with Ivosidenib. |
| Ketoconazole | The metabolism of Ivosidenib can be decreased when combined with Ketoconazole. |
| Ketorolac | The metabolism of Ketorolac can be increased when combined with Ivosidenib. |
| Lacidipine | The metabolism of Lacidipine can be increased when combined with Ivosidenib. |
| Lacosamide | The metabolism of Lacosamide can be increased when combined with Ivosidenib. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Ivosidenib. |
| Lanreotide | The metabolism of Ivosidenib can be decreased when combined with Lanreotide. |
| Lansoprazole | The metabolism of Lansoprazole can be increased when combined with Ivosidenib. |
| Lapatinib | The metabolism of Lapatinib can be increased when combined with Ivosidenib. |
| Larotrectinib | The metabolism of Larotrectinib can be increased when combined with Ivosidenib. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Ivosidenib. |
| Leflunomide | The metabolism of Leflunomide can be increased when combined with Ivosidenib. |
| Lemborexant | The serum concentration of Lemborexant can be decreased when it is combined with Ivosidenib. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ivosidenib. |
| Lercanidipine | The metabolism of Lercanidipine can be increased when combined with Ivosidenib. |
| Lesinurad | The metabolism of Lesinurad can be increased when combined with Ivosidenib. |
| Letermovir | The metabolism of Ivosidenib can be decreased when combined with Letermovir. |
| Letrozole | The metabolism of Letrozole can be increased when combined with Ivosidenib. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ivosidenib. |
| Levacetylmethadol | The metabolism of Levacetylmethadol can be increased when combined with Ivosidenib. |
| Levamlodipine | The metabolism of Levamlodipine can be increased when combined with Ivosidenib. |
| Levobupivacaine | The metabolism of Levobupivacaine can be increased when combined with Ivosidenib. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ivosidenib. |
| Levocetirizine | The metabolism of Levocetirizine can be increased when combined with Ivosidenib. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ivosidenib. |
| Levoketoconazole | The metabolism of Ivosidenib can be decreased when combined with Levoketoconazole. |
| Levomenthol | The metabolism of Levomenthol can be increased when combined with Ivosidenib. |
| Levomilnacipran | The metabolism of Levomilnacipran can be increased when combined with Ivosidenib. |
| Levonorgestrel | The metabolism of Levonorgestrel can be increased when combined with Ivosidenib. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Ivosidenib. |
| Lidocaine | The metabolism of Lidocaine can be increased when combined with Ivosidenib. |
| Lidoflazine | The metabolism of Lidoflazine can be increased when combined with Ivosidenib. |
| Linagliptin | The metabolism of Ivosidenib can be decreased when combined with Linagliptin. |
| Liotrix | The metabolism of Liotrix can be increased when combined with Ivosidenib. |
| Lisuride | The metabolism of Lisuride can be increased when combined with Ivosidenib. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Ivosidenib. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Ivosidenib. |
| Lomitapide | The metabolism of Lomitapide can be increased when combined with Ivosidenib. |
| Lonafarnib | The metabolism of Ivosidenib can be decreased when combined with Lonafarnib. |
| Loperamide | The metabolism of Loperamide can be increased when combined with Ivosidenib. |
| Lopinavir | The serum concentration of Ivosidenib can be increased when it is combined with Lopinavir. |
| Loratadine | The metabolism of Loratadine can be increased when combined with Ivosidenib. |
| Lorazepam | The metabolism of Lorazepam can be increased when combined with Ivosidenib. |
| Lorcaserin | The metabolism of Lorcaserin can be increased when combined with Ivosidenib. |
| Lorlatinib | The metabolism of Lorlatinib can be increased when combined with Ivosidenib. |
| Lornoxicam | The metabolism of Lornoxicam can be increased when combined with Ivosidenib. |
| Lorpiprazole | The metabolism of Lorpiprazole can be increased when combined with Ivosidenib. |
| Losartan | The metabolism of Losartan can be increased when combined with Ivosidenib. |
| Lovastatin | The metabolism of Ivosidenib can be decreased when combined with Lovastatin. |
| Luliconazole | The metabolism of Ivosidenib can be decreased when combined with Luliconazole. |
| Lumacaftor | The metabolism of Ivosidenib can be increased when combined with Lumacaftor. |
| Lumateperone | The serum concentration of Lumateperone can be decreased when it is combined with Ivosidenib. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Ivosidenib. |
| Lumiracoxib | The metabolism of Lumiracoxib can be increased when combined with Ivosidenib. |
| Lurasidone | The metabolism of Lurasidone can be increased when combined with Ivosidenib. |
| Lurbinectedin | The metabolism of Lurbinectedin can be increased when combined with Ivosidenib. |
| Lynestrenol | The metabolism of Lynestrenol can be increased when combined with Ivosidenib. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Ivosidenib. |
| Macitentan | The metabolism of Macitentan can be increased when combined with Ivosidenib. |
| Manidipine | The metabolism of Manidipine can be increased when combined with Ivosidenib. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ivosidenib. |
| Maraviroc | The metabolism of Maraviroc can be increased when combined with Ivosidenib. |
| Maribavir | The metabolism of Maribavir can be increased when combined with Ivosidenib. |
| Mavacamten | The serum concentration of Ivosidenib can be decreased when it is combined with Mavacamten. |
| Medrogestone | The metabolism of Medrogestone can be increased when combined with Ivosidenib. |
| Medroxyprogester | The metabolism of Medroxyprogesterone acetate can be increased when combined with Ivosidenib. |
| Medrysone | The metabolism of Medrysone can be increased when combined with Ivosidenib. |
| Mefenamic acid | The metabolism of Mefenamic acid can be increased when combined with Ivosidenib. |
| Mefloquine | The metabolism of Mefloquine can be increased when combined with Ivosidenib. |
| Megestrol acetate | The metabolism of Megestrol acetate can be increased when combined with Ivosidenib. |
| Meloxicam | The metabolism of Meloxicam can be increased when combined with Ivosidenib. |
| Meperidine | The metabolism of Meperidine can be increased when combined with Ivosidenib. |
| Mephenytoin | The metabolism of Mephenytoin can be increased when combined with Ivosidenib. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Mepivacaine. |
| Meprednisone | The metabolism of Meprednisone can be increased when combined with Ivosidenib. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ivosidenib. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Ivosidenib. |
| Mestranol | The metabolism of Mestranol can be increased when combined with Ivosidenib. |
| Methadone | The metabolism of Methadone can be increased when combined with Ivosidenib. |
| Methimazole | The metabolism of Ivosidenib can be decreased when combined with Methimazole. |
| Methotrexate | The metabolism of Methotrexate can be increased when combined with Ivosidenib. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ivosidenib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ivosidenib. |
| Methoxyflurane | The metabolism of Methoxyflurane can be increased when combined with Ivosidenib. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ivosidenib. |
| Methylene blue | The metabolism of Ivosidenib can be decreased when combined with Methylene blue. |
| Methylergometrine | The metabolism of Methylergometrine can be increased when combined with Ivosidenib. |
| Methylphenobarbital | The metabolism of Ivosidenib can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Methylprednisolone can be increased when combined with Ivosidenib. |
| Methylprednisone | The metabolism of Methylprednisone can be increased when combined with Ivosidenib. |
| Methyltestosterone | The metabolism of Methyltestosterone can be increased when combined with Ivosidenib. |
| Methysergide | The metabolism of Methysergide can be increased when combined with Ivosidenib. |
| Metoclopramide | The metabolism of Metoclopramide can be increased when combined with Ivosidenib. |
| Metreleptin | The metabolism of Ivosidenib can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Ivosidenib can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Ivosidenib can be increased when combined with Metyrapone. |
| Mexiletine | The metabolism of Mexiletine can be increased when combined with Ivosidenib. |
| Mianserin | The metabolism of Mianserin can be increased when combined with Ivosidenib. |
| Miconazole | The metabolism of Ivosidenib can be decreased when combined with Miconazole. |
| Midazolam | The metabolism of Midazolam can be increased when combined with Ivosidenib. |
| Midostaurin | The metabolism of Ivosidenib can be increased when combined with Midostaurin. |
| Mifepristone | The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Ivosidenib. |
| Milnacipran | The metabolism of Ivosidenib can be decreased when combined with Milnacipran. |
| Miocamycin | The metabolism of Ivosidenib can be decreased when combined with Miocamycin. |
| Mirabegron | The metabolism of Mirabegron can be increased when combined with Ivosidenib. |
| Mirtazapine | The metabolism of Mirtazapine can be increased when combined with Ivosidenib. |
| Mitapivat | The metabolism of Mitapivat can be increased when combined with Ivosidenib. |
| Mitotane | The metabolism of Ivosidenib can be increased when combined with Mitotane. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Ivosidenib. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Mobocertinib. |
| Modafinil | The metabolism of Modafinil can be increased when combined with Ivosidenib. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ivosidenib. |
| Mometasone | The metabolism of Mometasone furoate can be increased when combined with Ivosidenib. |
| Montelukast | The metabolism of Montelukast can be increased when combined with Ivosidenib. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Ivosidenib. |
| Morphine | The metabolism of Morphine can be increased when combined with Ivosidenib. |
| Mosunetuzumab | The metabolism of Ivosidenib can be decreased when combined with Mosunetuzumab. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ivosidenib. |
| Mycophenolate m | The metabolism of Mycophenolate mofetil can be increased when combined with Ivosidenib. |
| Nabilone | The metabolism of Nabilone can be increased when combined with Ivosidenib. |
| Nabumetone | The metabolism of Nabumetone can be increased when combined with Ivosidenib. |
| Nafcillin | The metabolism of Ivosidenib can be increased when combined with Nafcillin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Ivosidenib. |
| Naloxegol | The metabolism of Naloxegol can be increased when combined with Ivosidenib. |
| Naproxen | The metabolism of Naproxen can be increased when combined with Ivosidenib. |
| Nateglinide | The metabolism of Nateglinide can be increased when combined with Ivosidenib. |
| Nebivolol | The metabolism of Nebivolol can be increased when combined with Ivosidenib. |
| Nefazodone | The metabolism of Ivosidenib can be decreased when combined with Nefazodone. |
| Nelfinavir | The metabolism of Ivosidenib can be decreased when combined with Nelfinavir. |
| Neratinib | The metabolism of Neratinib can be increased when combined with Ivosidenib. |
| Netupitant | The metabolism of Ivosidenib can be decreased when combined with Netupitant. |
| Nevirapine | The metabolism of Nevirapine can be increased when combined with Ivosidenib. |
| Niacin | The metabolism of Ivosidenib can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Ivosidenib can be decreased when combined with Nicardipine. |
| Niclosamide | The metabolism of Niclosamide can be increased when combined with Ivosidenib. |
| Nifedipine | The metabolism of Nifedipine can be increased when combined with Ivosidenib. |
| Nilotinib | The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Ivosidenib. |
| Nilvadipine | The metabolism of Ivosidenib can be decreased when combined with Nilvadipine. |
| Nimesulide | The metabolism of Nimesulide can be increased when combined with Ivosidenib. |
| Nimodipine | The metabolism of Nimodipine can be increased when combined with Ivosidenib. |
| Nintedanib | The metabolism of Nintedanib can be increased when combined with Ivosidenib. |
| Nirmatrelvir | The metabolism of Nirmatrelvir can be increased when combined with Ivosidenib. |
| Nisoldipine | The metabolism of Nisoldipine can be increased when combined with Ivosidenib. |
| Nitrazepam | The metabolism of Nitrazepam can be increased when combined with Ivosidenib. |
| Nitrendipine | The metabolism of Nitrendipine can be increased when combined with Ivosidenib. |
| Nomegestrol | The metabolism of Nomegestrol can be increased when combined with Ivosidenib. |
| Nomegestrol aceta | The metabolism of Nomegestrol acetate can be increased when combined with Ivosidenib. |
| Norelgestromin | The metabolism of Norelgestromin can be increased when combined with Ivosidenib. |
| Norethisterone | The metabolism of Norethisterone can be increased when combined with Ivosidenib. |
| Norethynodrel | The metabolism of Norethynodrel can be increased when combined with Ivosidenib. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Ivosidenib. |
| Norgestimate | The metabolism of Norgestimate can be increased when combined with Ivosidenib. |
| Norgestrel | The metabolism of Norgestrel can be increased when combined with Ivosidenib. |
| Nortriptyline | The metabolism of Nortriptyline can be increased when combined with Ivosidenib. |
| Noscapine | The metabolism of Ivosidenib can be decreased when combined with Noscapine. |
| Nylidrin | The metabolism of Nylidrin can be increased when combined with Ivosidenib. |
| Octreotide | The serum concentration of Ivosidenib can be increased when it is combined with Octreotide. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Ivosidenib. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ivosidenib. |
| Olaparib | The metabolism of Olaparib can be increased when combined with Ivosidenib. |
| Oliceridine | The serum concentration of Oliceridine can be decreased when it is combined with Ivosidenib. |
| Olodaterol | The metabolism of Olodaterol can be increased when combined with Ivosidenib. |
| Omeprazole | The metabolism of Omeprazole can be increased when combined with Ivosidenib. |
| Ondansetron | The metabolism of Ondansetron can be increased when combined with Ivosidenib. |
| Opium | The metabolism of Opium can be increased when combined with Ivosidenib. |
| Oritavancin | The metabolism of Ivosidenib can be increased when combined with Oritavancin. |
| Orphenadrine | The metabolism of Orphenadrine can be increased when combined with Ivosidenib. |
| Osilodrostat | The metabolism of Osilodrostat can be increased when combined with Ivosidenib. |
| Osimertinib | The metabolism of Osimertinib can be increased when combined with Ivosidenib. |
| Ospemifene | The metabolism of Ospemifene can be increased when combined with Ivosidenib. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ivosidenib. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Ivosidenib. |
| Oxcarbazepine | The metabolism of Ivosidenib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Oxybutynin can be increased when combined with Ivosidenib. |
| Oxycodone | The metabolism of Oxycodone can be increased when combined with Ivosidenib. |
| Oxymorphone | The metabolism of Oxymorphone can be increased when combined with Ivosidenib. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivosidenib. |
| Paclitaxel | The metabolism of Paclitaxel can be increased when combined with Ivosidenib. |
| Pacritinib | The serum concentration of Ivosidenib can be increased when it is combined with Pacritinib. |
| Palbociclib | The metabolism of Palbociclib can be increased when combined with Ivosidenib. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ivosidenib. |
| Palonosetron | The metabolism of Palonosetron can be increased when combined with Ivosidenib. |
| Palovarotene | The metabolism of Palovarotene can be increased when combined with Ivosidenib. |
| Panobinostat | The metabolism of Panobinostat can be increased when combined with Ivosidenib. |
| Pantoprazole | The metabolism of Pantoprazole can be increased when combined with Ivosidenib. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ivosidenib. |
| Paramethadione | The metabolism of Paramethadione can be increased when combined with Ivosidenib. |
| Parecoxib | The metabolism of Parecoxib can be increased when combined with Ivosidenib. |
| Paricalcitol | The metabolism of Paricalcitol can be increased when combined with Ivosidenib. |
| Paritaprevir | The metabolism of Paritaprevir can be increased when combined with Ivosidenib. |
| Paroxetine | The metabolism of Paroxetine can be increased when combined with Ivosidenib. |
| Pasireotide | The metabolism of Ivosidenib can be decreased when combined with Pasireotide. |
| Pazopanib | The metabolism of Pazopanib can be increased when combined with Ivosidenib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ivosidenib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ivosidenib. |
| Pemigatinib | The metabolism of Pemigatinib can be increased when combined with Ivosidenib. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Ivosidenib. |
| Pentobarbital | The metabolism of Ivosidenib can be increased when combined with Pentobarbital. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Ivosidenib. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ivosidenib. |
| Perhexiline | The metabolism of Perhexiline can be increased when combined with Ivosidenib. |
| Pexidartinib | The metabolism of Pexidartinib can be increased when combined with Ivosidenib. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ivosidenib. |
| Phenobarbital | The metabolism of Ivosidenib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be increased when combined with Ivosidenib. |
| Phentermine | The metabolism of Phentermine can be increased when combined with Ivosidenib. |
| Phenylbutazone | The metabolism of Phenylbutazone can be increased when combined with Ivosidenib. |
| Phenytoin | The metabolism of Ivosidenib can be increased when combined with Phenytoin. |
| Pimavanserin | The metabolism of Pimavanserin can be increased when combined with Ivosidenib. |
| Pimecrolimus | The metabolism of Pimecrolimus can be increased when combined with Ivosidenib. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Pimozide is combined with Ivosidenib. |
| Pinacidil | The metabolism of Pinacidil can be increased when combined with Ivosidenib. |
| Pinaverium | The metabolism of Pinaverium can be increased when combined with Ivosidenib. |
| Pioglitazone | The metabolism of Pioglitazone can be increased when combined with Ivosidenib. |
| Piperaquine | The metabolism of Piperaquine can be increased when combined with Ivosidenib. |
| Pipotiazine | The metabolism of Pipotiazine can be increased when combined with Ivosidenib. |
| Pirfenidone | The metabolism of Pirfenidone can be increased when combined with Ivosidenib. |
| Piroxicam | The metabolism of Piroxicam can be increased when combined with Ivosidenib. |
| Pitavastatin | The metabolism of Pitavastatin can be increased when combined with Ivosidenib. |
| Pitolisant | The serum concentration of Ivosidenib can be decreased when it is combined with Pitolisant. |
| Polatuzumab ve | The metabolism of Polatuzumab vedotin can be increased when combined with Ivosidenib. |
| Pomalidomide | The metabolism of Pomalidomide can be increased when combined with Ivosidenib. |
| Ponatinib | The metabolism of Ponatinib can be increased when combined with Ivosidenib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Ivosidenib. |
| Posaconazole | The metabolism of Ivosidenib can be decreased when combined with Posaconazole. |
| Pralsetinib | The metabolism of Pralsetinib can be increased when combined with Ivosidenib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Pramocaine. |
| Prasterone | The metabolism of Prasterone can be increased when combined with Ivosidenib. |
| Prasugrel | The metabolism of Prasugrel can be increased when combined with Ivosidenib. |
| Prazepam | The metabolism of Prazepam can be increased when combined with Ivosidenib. |
| Praziquantel | The metabolism of Praziquantel can be increased when combined with Ivosidenib. |
| Prednicarbate | The metabolism of Prednicarbate can be increased when combined with Ivosidenib. |
| Prednisolone | The metabolism of Prednisolone can be increased when combined with Ivosidenib. |
| Prednisolone ace | The metabolism of Prednisolone acetate can be increased when combined with Ivosidenib. |
| Prednisolone p | The metabolism of Prednisolone phosphate can be increased when combined with Ivosidenib. |
| Prednisone | The metabolism of Prednisone can be increased when combined with Ivosidenib. |
| Prednisone acetate | The metabolism of Ivosidenib can be increased when combined with Prednisone acetate. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ivosidenib. |
| Pregnenolone | The metabolism of Pregnenolone can be increased when combined with Ivosidenib. |
| Prenylamine | The metabolism of Prenylamine can be increased when combined with Ivosidenib. |
| Pretomanid | The metabolism of Pretomanid can be increased when combined with Ivosidenib. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Prilocaine. |
| Primaquine | The metabolism of Ivosidenib can be decreased when combined with Primaquine. |
| Primidone | The metabolism of Ivosidenib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Ivosidenib can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Ivosidenib. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ivosidenib. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Procaine. |
| Prochlorperazine | The metabolism of Prochlorperazine can be increased when combined with Ivosidenib. |
| Progesterone | The metabolism of Progesterone can be increased when combined with Ivosidenib. |
| Proguanil | The metabolism of Proguanil can be increased when combined with Ivosidenib. |
| Promazine | The metabolism of Promazine can be increased when combined with Ivosidenib. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ivosidenib. |
| Propafenone | The metabolism of Propafenone can be increased when combined with Ivosidenib. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Proparacaine. |
| Propiverine | The metabolism of Propiverine can be increased when combined with Ivosidenib. |
| Propofol | The metabolism of Propofol can be increased when combined with Ivosidenib. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Propoxycaine. |
| Propranolol | The metabolism of Propranolol can be increased when combined with Ivosidenib. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ivosidenib. |
| Prucalopride | The metabolism of Prucalopride can be increased when combined with Ivosidenib. |
| Quazepam | The metabolism of Quazepam can be increased when combined with Ivosidenib. |
| Quetiapine | The metabolism of Quetiapine can be increased when combined with Ivosidenib. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Quinidine is combined with Ivosidenib. |
| Quinine | The risk or severity of QTc prolongation can be increased when Quinine is combined with Ivosidenib. |
| Quinupristin | The metabolism of Ivosidenib can be decreased when combined with Quinupristin. |
| Raloxifene | The metabolism of Ivosidenib can be decreased when combined with Raloxifene. |
| Ramelteon | The metabolism of Ramelteon can be increased when combined with Ivosidenib. |
| Ranolazine | The metabolism of Ranolazine can be increased when combined with Ivosidenib. |
| Reboxetine | The metabolism of Reboxetine can be increased when combined with Ivosidenib. |
| Regorafenib | The metabolism of Regorafenib can be increased when combined with Ivosidenib. |
| Relugolix | The metabolism of Relugolix can be increased when combined with Ivosidenib. |
| Remdesivir | The metabolism of Remdesivir can be increased when combined with Ivosidenib. |
| Repaglinide | The metabolism of Repaglinide can be increased when combined with Ivosidenib. |
| Retapamulin | The metabolism of Retapamulin can be increased when combined with Ivosidenib. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Ivosidenib. |
| Rifabutin | The metabolism of Rifabutin can be increased when combined with Ivosidenib. |
| Rifampicin | The metabolism of Ivosidenib can be increased when combined with Rifampicin. |
| Rifamycin | The metabolism of Ivosidenib can be increased when combined with Rifamycin. |
| Rifapentine | The metabolism of Ivosidenib can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Ivosidenib can be increased when combined with Rilonacept. |
| Rilpivirine | The metabolism of Rilpivirine can be increased when combined with Ivosidenib. |
| Rimegepant | The metabolism of Rimegepant can be increased when combined with Ivosidenib. |
| Rimexolone | The metabolism of Ivosidenib can be increased when combined with Rimexolone. |
| Rimonabant | The metabolism of Rimonabant can be increased when combined with Ivosidenib. |
| Riociguat | The metabolism of Riociguat can be increased when combined with Ivosidenib. |
| Ripretinib | The metabolism of Ripretinib can be increased when combined with Ivosidenib. |
| Risperidone | The metabolism of Risperidone can be increased when combined with Ivosidenib. |
| Ritonavir | The serum concentration of Ivosidenib can be increased when it is combined with Ritonavir. |
| Rivaroxaban | The metabolism of Rivaroxaban can be increased when combined with Ivosidenib. |
| Rofecoxib | The metabolism of Rofecoxib can be increased when combined with Ivosidenib. |
| Roflumilast | The metabolism of Roflumilast can be increased when combined with Ivosidenib. |
| Rolapitant | The metabolism of Rolapitant can be increased when combined with Ivosidenib. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ivosidenib. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Ropivacaine. |
| Rosiglitazone | The metabolism of Rosiglitazone can be increased when combined with Ivosidenib. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ivosidenib. |
| Rosuvastatin | The metabolism of Rosuvastatin can be increased when combined with Ivosidenib. |
| Rotigotine | The metabolism of Rotigotine can be increased when combined with Ivosidenib. |
| Roxithromycin | The metabolism of Roxithromycin can be increased when combined with Ivosidenib. |
| Rucaparib | The metabolism of Rucaparib can be increased when combined with Ivosidenib. |
| Rufinamide | The metabolism of Ivosidenib can be increased when combined with Rufinamide. |
| Rupatadine | The metabolism of Rupatadine can be increased when combined with Ivosidenib. |
| Ruxolitinib | The metabolism of Ruxolitinib can be increased when combined with Ivosidenib. |
| Safinamide | The metabolism of Safinamide can be increased when combined with Ivosidenib. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ivosidenib. |
| Salicylic acid | The metabolism of Salicylic acid can be increased when combined with Ivosidenib. |
| Salmeterol | The metabolism of Salmeterol can be increased when combined with Ivosidenib. |
| Samidorphan | The metabolism of Samidorphan can be increased when combined with Ivosidenib. |
| Saquinavir | The metabolism of Ivosidenib can be decreased when combined with Saquinavir. |
| Sarilumab | The metabolism of Ivosidenib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Ivosidenib can be decreased when it is combined with Satralizumab. |
| Saxagliptin | The metabolism of Saxagliptin can be increased when combined with Ivosidenib. |
| Scopolamine | The metabolism of Scopolamine can be increased when combined with Ivosidenib. |
| Secobarbital | The metabolism of Ivosidenib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Ivosidenib can be increased when combined with Secukinumab. |
| Segesterone ac | The metabolism of Segesterone acetate can be increased when combined with Ivosidenib. |
| Selegiline | The metabolism of Selegiline can be increased when combined with Ivosidenib. |
| Selexipag | The metabolism of Selexipag can be increased when combined with Ivosidenib. |
| Selinexor | The metabolism of Selinexor can be increased when combined with Ivosidenib. |
| Selpercatinib | The serum concentration of Selpercatinib can be decreased when it is combined with Ivosidenib. |
| Selumetinib | The metabolism of Selumetinib can be increased when combined with Ivosidenib. |
| Sertindole | The metabolism of Sertindole can be increased when combined with Ivosidenib. |
| Sertraline | The metabolism of Sertraline can be increased when combined with Ivosidenib. |
| Sevoflurane | The metabolism of Sevoflurane can be increased when combined with Ivosidenib. |
| Sibutramine | The metabolism of Sibutramine can be increased when combined with Ivosidenib. |
| Sildenafil | The metabolism of Sildenafil can be increased when combined with Ivosidenib. |
| Silodosin | The metabolism of Silodosin can be increased when combined with Ivosidenib. |
| Siltuximab | The metabolism of Ivosidenib can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Ivosidenib can be decreased when combined with Simeprevir. |
| Simvastatin | The metabolism of Simvastatin can be increased when combined with Ivosidenib. |
| Siponimod | The metabolism of Siponimod can be increased when combined with Ivosidenib. |
| Sirolimus | The metabolism of Sirolimus can be increased when combined with Ivosidenib. |
| Sitagliptin | The metabolism of Sitagliptin can be increased when combined with Ivosidenib. |
| Sitaxentan | The metabolism of Sitaxentan can be increased when combined with Ivosidenib. |
| Solifenacin | The metabolism of Solifenacin can be increased when combined with Ivosidenib. |
| Somatostatin | The metabolism of Ivosidenib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Ivosidenib can be increased when combined with Somatrogon. |
| Sonidegib | The metabolism of Sonidegib can be increased when combined with Ivosidenib. |
| Sorafenib | The metabolism of Sorafenib can be increased when combined with Ivosidenib. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ivosidenib. |
| Sotorasib | The serum concentration of Ivosidenib can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Ivosidenib. |
| St. John’s Wort | The metabolism of Ivosidenib can be increased when combined with St. John’s Wort. |
| Stiripentol | The metabolism of Ivosidenib can be decreased when combined with Stiripentol. |
| Sufentanil | The metabolism of Sufentanil can be increased when combined with Ivosidenib. |
| Sulfadiazine | The metabolism of Sulfadiazine can be increased when combined with Ivosidenib. |
| Sulfamethoxazole | The metabolism of Sulfamethoxazole can be increased when combined with Ivosidenib. |
| Sulfinpyrazone | The metabolism of Sulfinpyrazone can be increased when combined with Ivosidenib. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Ivosidenib. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Ivosidenib. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Sultopride is combined with Ivosidenib. |
| Sunitinib | The metabolism of Sunitinib can be increased when combined with Ivosidenib. |
| Suprofen | The metabolism of Suprofen can be increased when combined with Ivosidenib. |
| Suvorexant | The metabolism of Suvorexant can be increased when combined with Ivosidenib. |
| SynEstrogens, A | The metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Ivosidenib. |
| SyEstrogens, B | The metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Ivosidenib. |
| Tacrolimus | The metabolism of Tacrolimus can be increased when combined with Ivosidenib. |
| Tadalafil | The metabolism of Tadalafil can be increased when combined with Ivosidenib. |
| Tamoxifen | The metabolism of Tamoxifen can be increased when combined with Ivosidenib. |
| Tamsulosin | The metabolism of Tamsulosin can be increased when combined with Ivosidenib. |
| Tasimelteon | The metabolism of Tasimelteon can be increased when combined with Ivosidenib. |
| Tazemetostat | The metabolism of Tazemetostat can be increased when combined with Ivosidenib. |
| Tecovirimat | The metabolism of Ivosidenib can be increased when combined with Tecovirimat. |
| Telaprevir | The metabolism of Ivosidenib can be decreased when combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Ivosidenib. |
| Telithromycin | The metabolism of Ivosidenib can be decreased when combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Ivosidenib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The metabolism of Temsirolimus can be increased when combined with Ivosidenib. |
| Teniposide | The metabolism of Teniposide can be increased when combined with Ivosidenib. |
| Tenofovir alafe | The metabolism of Tenofovir alafenamide can be increased when combined with Ivosidenib. |
| Tenoxicam | The metabolism of Tenoxicam can be increased when combined with Ivosidenib. |
| Tepotinib | The metabolism of Tepotinib can be increased when combined with Ivosidenib. |
| Terbinafine | The metabolism of Terbinafine can be increased when combined with Ivosidenib. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ivosidenib. |
| Terfenadine | The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Ivosidenib. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Ivosidenib. |
| Testosterone | The metabolism of Testosterone can be increased when combined with Ivosidenib. |
| Testosterone cyp | The metabolism of Testosterone cypionate can be increased when combined with Ivosidenib. |
| Testosterone enan | The metabolism of Testosterone enanthate can be increased when combined with Ivosidenib. |
| Testosterone pro | The metabolism of Testosterone propionate can be increased when combined with Ivosidenib. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Ivosidenib. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Tetracaine. |
| Tetracycline | The metabolism of Tetracycline can be increased when combined with Ivosidenib. |
| Tezacaftor | The metabolism of Tezacaftor can be increased when combined with Ivosidenib. |
| Thalidomide | The metabolism of Thalidomide can be increased when combined with Ivosidenib. |
| Theophylline | The metabolism of Theophylline can be increased when combined with Ivosidenib. |
| Thiamylal | The metabolism of Thiamylal can be increased when combined with Ivosidenib. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Ivosidenib. |
| Thiotepa | The metabolism of Thiotepa can be increased when combined with Ivosidenib. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ivosidenib. |
| Tiagabine | The metabolism of Tiagabine can be increased when combined with Ivosidenib. |
| Ticagrelor | The metabolism of Ticagrelor can be increased when combined with Ivosidenib. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Ivosidenib. |
| Tinidazole | The metabolism of Tinidazole can be increased when combined with Ivosidenib. |
| Tioconazole | The metabolism of Ivosidenib can be decreased when combined with Tioconazole. |
| Tiotropium | The metabolism of Tiotropium can be increased when combined with Ivosidenib. |
| Tipranavir | The metabolism of Ivosidenib can be decreased when combined with Tipranavir. |
| Tisotumab vedotin | The metabolism of Tisotumab vedotin can be increased when combined with Ivosidenib. |
| Tivozanib | The metabolism of Tivozanib can be increased when combined with Ivosidenib. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ivosidenib. |
| Tocilizumab | The metabolism of Ivosidenib can be increased when combined with Tocilizumab. |
| Tocofersolan | The metabolism of Tocofersolan can be increased when combined with Ivosidenib. |
| Tocopherol | The metabolism of Tocopherol can be increased when combined with Ivosidenib. |
| Tofacitinib | The metabolism of Tofacitinib can be increased when combined with Ivosidenib. |
| Tolazamide | The metabolism of Tolazamide can be increased when combined with Ivosidenib. |
| Tolbutamide | The metabolism of Tolbutamide can be increased when combined with Ivosidenib. |
| Tolfenamic acid | The metabolism of Tolfenamic acid can be increased when combined with Ivosidenib. |
| Tolterodine | The metabolism of Tolterodine can be increased when combined with Ivosidenib. |
| Tolvaptan | The metabolism of Tolvaptan can be increased when combined with Ivosidenib. |
| Topiramate | The metabolism of Ivosidenib can be increased when combined with Topiramate. |
| Torasemide | The metabolism of Torasemide can be increased when combined with Ivosidenib. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Toremifene is combined with Ivosidenib. |
| Trabectedin | The metabolism of Trabectedin can be increased when combined with Ivosidenib. |
| Tramadol | The metabolism of Tramadol can be increased when combined with Ivosidenib. |
| Trastuzumab emte | The metabolism of Trastuzumab emtansine can be increased when combined with Ivosidenib. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ivosidenib. |
| Treprostinil | The metabolism of Treprostinil can be increased when combined with Ivosidenib. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Ivosidenib. |
| Triamcinolone | The metabolism of Triamcinolone can be increased when combined with Ivosidenib. |
| Triazolam | The metabolism of Triazolam can be increased when combined with Ivosidenib. |
| Triclabendazole | The metabolism of Triclabendazole can be increased when combined with Ivosidenib. |
| Trimebutine | The metabolism of Trimebutine can be increased when combined with Ivosidenib. |
| Trimethadione | The metabolism of Trimethadione can be increased when combined with Ivosidenib. |
| Trimethoprim | The metabolism of Trimethoprim can be increased when combined with Ivosidenib. |
| Trimipramine | The metabolism of Trimipramine can be increased when combined with Ivosidenib. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ivosidenib. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ivosidenib. |
| Troglitazone | The metabolism of Troglitazone can be increased when combined with Ivosidenib. |
| Troleandomycin | The metabolism of Ivosidenib can be decreased when combined with Troleandomycin. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Ivosidenib. |
| Tucatinib | The metabolism of Tucatinib can be decreased when combined with Ivosidenib. |
| Ubrogepant | The metabolism of Ubrogepant can be increased when combined with Ivosidenib. |
| Udenafil | The metabolism of Udenafil can be increased when combined with Ivosidenib. |
| Ulipristal | The metabolism of Ulipristal can be increased when combined with Ivosidenib. |
| Upadacitinib | The metabolism of Upadacitinib can be increased when combined with Ivosidenib. |
| Valbenazine | The metabolism of Valbenazine can be increased when combined with Ivosidenib. |
| Valdecoxib | The metabolism of Valdecoxib can be increased when combined with Ivosidenib. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivosidenib. |
| Valsartan | The metabolism of Valsartan can be increased when combined with Ivosidenib. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Ivosidenib. |
| Vardenafil | The metabolism of Vardenafil can be increased when combined with Ivosidenib. |
| Velpatasvir | The metabolism of Velpatasvir can be increased when combined with Ivosidenib. |
| Vemurafenib | The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ivosidenib. |
| Venetoclax | The metabolism of Ivosidenib can be decreased when combined with Venetoclax. |
| Venlafaxine | The metabolism of Venlafaxine can be increased when combined with Ivosidenib. |
| Verapamil | The metabolism of Ivosidenib can be decreased when combined with Verapamil. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Ivosidenib. |
| Vilanterol | The metabolism of Vilanterol can be increased when combined with Ivosidenib. |
| Vilazodone | The metabolism of Vilazodone can be increased when combined with Ivosidenib. |
| Viloxazine | The metabolism of Ivosidenib can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Vinblastine can be increased when combined with Ivosidenib. |
| Vincristine | The metabolism of Vincristine can be increased when combined with Ivosidenib. |
| Vindesine | The metabolism of Vindesine can be increased when combined with Ivosidenib. |
| Vinflunine | The metabolism of Vinflunine can be increased when combined with Ivosidenib. |
| Vinorelbine | The metabolism of Vinorelbine can be increased when combined with Ivosidenib. |
| Vismodegib | The metabolism of Vismodegib can be increased when combined with Ivosidenib. |
| Vitamin D | The metabolism of Vitamin D can be increased when combined with Ivosidenib. |
| Vitamin E | The metabolism of Vitamin E can be increased when combined with Ivosidenib. |
| Voclosporin | The metabolism of Voclosporin can be increased when combined with Ivosidenib. |
| Vonoprazan | The metabolism of Vonoprazan can be increased when combined with Ivosidenib. |
| Vorapaxar | The metabolism of Vorapaxar can be increased when combined with Ivosidenib. |
| Voriconazole | The metabolism of Ivosidenib can be decreased when combined with Voriconazole. |
| Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Ivosidenib. |
| Vortioxetine | The metabolism of Vortioxetine can be increased when combined with Ivosidenib. |
| Voxelotor | The serum concentration of Ivosidenib can be increased when it is combined with Voxelotor. |
| Voxilaprevir | The metabolism of Voxilaprevir can be increased when combined with Ivosidenib. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Ivosidenib. |
| Ximelagatran | The metabolism of Ximelagatran can be increased when combined with Ivosidenib. |
| Yohimbine | The metabolism of Yohimbine can be increased when combined with Ivosidenib. |
| Zafirlukast | The metabolism of Zafirlukast can be increased when combined with Ivosidenib. |
| Zaleplon | The metabolism of Zaleplon can be increased when combined with Ivosidenib. |
| Zanubrutinib | The metabolism of Zanubrutinib can be increased when combined with Ivosidenib. |
| Zidovudine | The metabolism of Zidovudine can be increased when combined with Ivosidenib. |
| Zileuton | The metabolism of Zileuton can be increased when combined with Ivosidenib. |
| Zimelidine | The metabolism of Ivosidenib can be decreased when combined with Zimelidine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Ziprasidone. |
| Zolpidem | The metabolism of Zolpidem can be increased when combined with Ivosidenib. |
| Zonisamide | The metabolism of Zonisamide can be increased when combined with Ivosidenib. |
| Zopiclone | The metabolism of Zopiclone can be increased when combined with Ivosidenib. |
| Zotepine | The metabolism of Zotepine can be increased when combined with Ivosidenib. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Ivosidenib. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
Based on animal embryo-fetal toxicity studies, TIBSOVO may cause fetal harm when administered to a pregnant woman. There are no available data on TIBSOVO use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal
embryo-fetal toxicity studies, oral administration of ivosidenib to pregnant rats and rabbits during organogenesis was associated with embryo-fetal mortality and alterations to growth starting at 2 times the steady-state clinical exposure based on the AUC at the recommended
human dose (see Data). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus.
Lactation
There are no data on the presence of ivosidenib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO and for at least 1 month after the last dose.
Why is this medication prescribed?
Ivosidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has returned or that has not improved after previous treatment(s). Ivosidenib is also used alone or in combination with azacitidine (Onureg) to treat a certain type of AML in some adults older than 75 years of age as a first treatment. Ivosidenib is also used in adults who have already received previous treatment(s) to treat a certain type of cholangiocarcinoma (bile duct cancer) that has spread to nearby tissues or other parts of the body. Ivosidenib is in a class of medications called IDH1 inhibitors. It works by slowing or stopping the growth of cancer cells.
How should this medicine be used?
Ivosidenib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Do not take it with high-fat food such as eggs, butter, whole-milk dairy products (such as whole milk, cheese, and yogurt), fried foods, or fast food. Take ivosidenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ivosidenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them. If you vomit after taking ivosidenib, do not take another dose. Continue your regular dosing schedule.
Your doctor may reduce your dose or temporarily or permanently stop your treatment with ivosidenib depending on your response to treatment or any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking ivosidenib,
- tell your doctor and pharmacist if you are allergic to ivosidenib, any other medications, or any of the ingredients in ivosidenib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you or anyone in your family has or has ever had a prolonged QT interval (a condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death); if you have or have ever had a slow or irregular heartbeat, heart failure, or other heart problems; low blood levels of sodium, potassium, calcium, or magnesium; nervous system problems; liver disease, including cirrhosis; or if you are receiving dialysis treatments or if you have or ever had kidney disease.
- tell your doctor if you are pregnant or plan to become pregnant, or are breastfeeding. You should know that ivosidenib may decrease the effectiveness of hormonal contraceptives (birth control pills, patches, rings, or injections) while you are taking this medication. Talk to your doctor about using another form of birth control. If you become pregnant while taking ivosidenib, call your doctor immediately. Ivosidenib may cause fetal harm.
- tell your doctor if are breastfeeding. Do not breastfeed during your treatment with ivosidenib and for 1 month after your final dose.
What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet. Make sure you drink plenty of water or other fluids every day while you are taking ivosidenib.
What should I do if I forget a dose?
If your next dose is due in 12 hours or more, take the missed dose as soon as you remember it. However, if the next dose will be taken in less than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
References
Shop From Rxharun..
About Us...
Editorial Board Members..
Developers Team...
Team Rxharun.